{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T03:12:21Z","timestamp":1791947541823,"version":"4.3.4"},"reference-count":31,"publisher":"American Society of Hematology","issue":"5","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2026,3,10]]},"abstract":"<jats:sec>\n                    <jats:title>Abstract<\/jats:title>\n                    <jats:p>Myeloproliferative neoplasms (MPNs), including polycythemia vera (PV), essential thrombocythemia (ET), and myelofibrosis (MF), are chronic myeloid neoplasms associated with increased risk of cardiovascular disease (CVD). Statins are a common group of cholesterol-lowering medications recommended for the primary and secondary prevention of CVD, including arterial thrombotic events. Emerging evidence suggests that statins may reduce the risk of developing MPNs and their use may be associated with improved survival. However, the effect of statins on cardiovascular and hematologic outcomes among patients with MPNs remains uncharacterized. We conducted a multicenter retrospective cohort study of patients with MPNs who had at least 1 transthoracic echocardiogram (TTE) from 2010 to 2024. Inverse probability of treatment weighting (IPTW) competing-risk regression analysis was performed to assess the association between statin use at time of index TTE on major adverse cardiovascular events (MACE), MPN disease progression, and all-cause death. Patients with MPN were analyzed as a whole and separately by type (ET or PV and MF). A total of 669 patients were included, 43.9% were on statin use, 50.5% were female, 83.9% were White, 78.8% had JAK2 driver mutation, and 72.9% had class I guideline indication for statin therapy. There were 267 (39.9%) patients with PV, 234 (35.0%) with ET, and 168 (25.1%) with MF. After IPTW, statin use was associated with lower risk of MACE but not MPN disease progression or all-cause death. Among patients with ET or PV, statin use was associated with lower risk of MACE but not MPN progression or all-cause death. Among patients with MF, there was no difference in MACE, leukemia progression, or all-cause death. Among patients with MPNs who underwent TTE, statin use was associated with lower risk of MACE, particularly among patients with ET or PV. However, there was no association between statin use and all-cause death or MPN disease progression. Statin therapy is underused in this patient population. Further studies are needed to explore the utility of statin therapy in patients with MPN and identify patients who would benefit most from statin therapy.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1182\/bloodadvances.2025018724","type":"journal-article","created":{"date-parts":[[2026,1,7]],"date-time":"2026-01-07T22:00:52Z","timestamp":1767823252000},"page":"1603-1613","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":7,"title":["Impact of statin use on cardiovascular and hematologic outcomes among patients with myeloproliferative neoplasms"],"prefix":"10.1182","volume":"10","author":[{"given":"Orly","family":"Leiva","sequence":"first","affiliation":[{"name":"1Gill Heart & Vascular Institute, University of Kentucky College of Medicine, Lexington, KY"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steven","family":"Soo","sequence":"additional","affiliation":[{"name":"2Division of Cardiology, Department of Medicine, New York University Grossman School of Medicine, New York, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4995-4863","authenticated-orcid":false,"given":"Olivia C.","family":"Liu","sequence":"additional","affiliation":[{"name":"2Division of Cardiology, Department of Medicine, New York University Grossman School of Medicine, New York, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4734-6557","authenticated-orcid":false,"given":"Victor","family":"You","sequence":"additional","affiliation":[{"name":"3Division of Hematology and Oncology, Department of Medicine, Massachusetts General Hospital and Harvard Medical School, Boston, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0008-5239-0676","authenticated-orcid":false,"given":"Andrew","family":"Palmer","sequence":"additional","affiliation":[{"name":"4Section of Cardiology, Department of Medicine, University of Chicago, Chicago, IL"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Justin","family":"Kahla","sequence":"additional","affiliation":[{"name":"4Section of Cardiology, Department of Medicine, University of Chicago, Chicago, IL"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasmeen","family":"Murtaza","sequence":"additional","affiliation":[{"name":"4Section of Cardiology, Department of Medicine, University of Chicago, Chicago, IL"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olatoyosi","family":"Odenike","sequence":"additional","affiliation":[{"name":"5Section of Hematology and Oncology, Department of Medicine, University of Chicago, Chicago, IL"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0296-8686","authenticated-orcid":false,"given":"Anand A.","family":"Patel","sequence":"additional","affiliation":[{"name":"5Section of Hematology and Oncology, Department of Medicine, University of Chicago, Chicago, IL"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeanne M.","family":"DeCara","sequence":"additional","affiliation":[{"name":"4Section of Cardiology, Department of Medicine, University of Chicago, Chicago, IL"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3987-0647","authenticated-orcid":false,"given":"Patrycja M.","family":"Dubielecka","sequence":"additional","affiliation":[{"name":"6Division of Hematology\/Oncology, Rhode Island Hospital and Warren Alpert Medical School of Brown University, Providence, RI"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Max","family":"Petersen","sequence":"additional","affiliation":[{"name":"6Division of Hematology\/Oncology, Rhode Island Hospital and Warren Alpert Medical School of Brown University, Providence, RI"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7847-4471","authenticated-orcid":false,"given":"Michelle Hyunju","family":"Lee","sequence":"additional","affiliation":[{"name":"3Division of Hematology and Oncology, Department of Medicine, Massachusetts General Hospital and Harvard Medical School, Boston, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6421-0117","authenticated-orcid":false,"given":"Joan","family":"How","sequence":"additional","affiliation":[{"name":"7Division of Hematology, Department of Medicine, Brigham and Women\u2019s Hospital and Harvard Medical School, Boston, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0199-9333","authenticated-orcid":false,"given":"Gabriela","family":"Hobbs","sequence":"additional","affiliation":[{"name":"3Division of Hematology and Oncology, Department of Medicine, Massachusetts General Hospital and Harvard Medical School, Boston, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","published-online":{"date-parts":[[2026,2,27]]},"reference":[{"issue":"10","key":"2026030916264695900_bib1","doi-asserted-by":"crossref","first-page":"1257","DOI":"10.1007\/s11864-024-01255-8","article-title":"Myeloproliferative neoplasms and cardiovascular disease: a review","volume":"25","author":"Leiva","year":"2024","journal-title":"Curr Treat Options Oncol"},{"issue":"2","key":"2026030916264695900_bib2","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1016\/j.jaccao.2022.04.002","article-title":"Cardiovascular disease in myeloproliferative neoplasms: JACC: CardioOncology state-of-the-art review","volume":"4","author":"Leiva","year":"2022","journal-title":"JACC CardioOncol"},{"issue":"5","key":"2026030916264695900_bib3","doi-asserted-by":"crossref","first-page":"538","DOI":"10.1016\/j.jaccao.2025.05.010","article-title":"Beyond thrombosis: pulmonary hypertension and heart failure in patients with myeloproliferative neoplasms: JACC: CardioOncology state-of-the-art review","volume":"7","author":"Leiva","year":"2025","journal-title":"JACC CardioOncol"},{"issue":"23","key":"2026030916264695900_bib4","doi-asserted-by":"crossref","first-page":"2205","DOI":"10.1093\/eurheartj\/ehaf114","article-title":"Plaque erosion risk and JAK2 V617F variant","volume":"46","author":"Wang","year":"2025","journal-title":"Eur Heart J"},{"issue":"11","key":"2026030916264695900_bib5","first-page":"e596","article-title":"2019 ACC\/AHA guideline on the primary prevention of cardiovascular disease: a report of the American College of Cardiology\/American Heart Association Task Force on clinical practice guidelines","volume":"140","author":"Arnett","year":"2019","journal-title":"Circulation"},{"issue":"25","key":"2026030916264695900_bib6","first-page":"e1082","article-title":"2018 AHA\/ACC\/AACVPR\/AAPA\/ABC\/ACPM\/ADA\/AGS\/APhA\/ASPC\/NLA\/PCNA guideline on the management of blood cholesterol: a report of the American College of Cardiology\/American Heart Association Task Force on Clinical Practice Guidelines","volume":"139","author":"Grundy","year":"2019","journal-title":"Circulation"},{"issue":"4A","key":"2026030916264695900_bib7","doi-asserted-by":"crossref","first-page":"4B","DOI":"10.1016\/S0002-9149(02)03267-8","article-title":"Mechanisms of plaque stabilization with statins","volume":"91","author":"Libby","year":"2003","journal-title":"Am J Cardiol"},{"issue":"12","key":"2026030916264695900_bib8","doi-asserted-by":"crossref","first-page":"2601","DOI":"10.3109\/10428194.2013.790022","article-title":"Antileukemic properties of 3-hydroxy-3-methylglutaryl-coenzyme A reductase inhibitors","volume":"54","author":"van Besien","year":"2013","journal-title":"Leuk Lymphoma"},{"issue":"14","key":"2026030916264695900_bib9","doi-asserted-by":"crossref","first-page":"3450","DOI":"10.1182\/bloodadvances.2023009784","article-title":"Use of statins and risk of myeloproliferative neoplasms: a Danish nationwide case-control study","volume":"7","author":"Tuyet Kristensen","year":"2023","journal-title":"Blood Adv"},{"issue":"4","key":"2026030916264695900_bib10","doi-asserted-by":"crossref","first-page":"911","DOI":"10.1007\/s00277-020-03950-6","article-title":"The impact of statins on the intensity of phlebotomies in polycythemia vera","volume":"99","author":"Kre\u010dak","year":"2020","journal-title":"Ann Hematol"},{"issue":"23","key":"2026030916264695900_bib11","doi-asserted-by":"crossref","first-page":"6189","DOI":"10.1182\/bloodadvances.2025017016","article-title":"Statins enhance the efficacy of pegylated interferon-alpha2 in Philadelphia-negative chronic myeloproliferative neoplasms","volume":"9","author":"Davidsen","year":"2025","journal-title":"Blood Adv"},{"issue":"7","key":"2026030916264695900_bib12","doi-asserted-by":"crossref","first-page":"1703","DOI":"10.1038\/s41375-022-01613-1","article-title":"The 5th edition of the World Health Organization classification of haematolymphoid tumours: myeloid and histiocytic\/dendritic neoplasms","volume":"36","author":"Khoury","year":"2022","journal-title":"Leukemia"},{"issue":"20","key":"2026030916264695900_bib13","doi-asserted-by":"crossref","first-page":"2391","DOI":"10.1182\/blood-2016-03-643544","article-title":"The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia","volume":"127","author":"Arber","year":"2016","journal-title":"Blood"},{"issue":"10","key":"2026030916264695900_bib14","first-page":"2388","article-title":"Characterization and prognostic implication of pulmonary hypertension among patients with myeloproliferative neoplasms","volume":"110","author":"Leiva","year":"2025","journal-title":"Haematologica"},{"issue":"8","key":"2026030916264695900_bib15","doi-asserted-by":"crossref","first-page":"e017986","DOI":"10.1161\/CIRCIMAGING.124.017986","article-title":"Impact of echocardiographic probability of pulmonary hypertension on prognosis and outcomes among patients with myeloproliferative neoplasms","volume":"18","author":"Leiva","year":"2025","journal-title":"Circ Cardiovasc Imaging"},{"issue":"9","key":"2026030916264695900_bib16","doi-asserted-by":"crossref","first-page":"e9","DOI":"10.1161\/CIR.0000000000001168","article-title":"AHA\/ACC\/ACCP\/ASPC\/NLA\/PCNA guideline for the management of patients with chronic coronary disease: a report of the American Heart Association\/American College of Cardiology Joint Committee on Clinical Practice Guidelines","volume":"148","author":"Virani","year":"2023","journal-title":"Circulation"},{"issue":"7","key":"2026030916264695900_bib17","doi-asserted-by":"crossref","first-page":"e364","DOI":"10.1161\/STR.0000000000000375","article-title":"2021 guideline for the prevention of stroke in patients with stroke and transient ischemic attack: a guideline from the American Heart Association\/American Stroke Association","volume":"52","author":"Kleindorfer","year":"2021","journal-title":"Stroke"},{"issue":"22","key":"2026030916264695900_bib18","doi-asserted-by":"crossref","first-page":"2135","DOI":"10.1016\/j.jacc.2024.11.009","article-title":"ACC\/AHA\/ACEP\/NAEMSP\/SCAI guideline for the management of patients with acute coronary syndromes: a report of the American College of Cardiology\/American Heart Association Joint Committee on Clinical Practice Guidelines","volume":"85","author":"Rao","year":"2025","journal-title":"J Am Coll Cardiol"},{"key":"2026030916264695900_bib19","doi-asserted-by":"crossref","first-page":"l5657","DOI":"10.1136\/bmj.l5657","article-title":"Alternative approaches for confounding adjustment in observational studies using weighting based on the propensity score: a primer for practitioners","volume":"367","author":"Desai","year":"2019","journal-title":"BMJ"},{"issue":"10","key":"2026030916264695900_bib20","doi-asserted-by":"crossref","first-page":"1071","DOI":"10.1001\/jamacardio.2025.2725","article-title":"Statin eligibility according to atherosclerotic cardiovascular disease risk in the US","volume":"10","author":"Khan","year":"2025","journal-title":"JAMA Cardiol"},{"issue":"5","key":"2026030916264695900_bib21","doi-asserted-by":"crossref","first-page":"640","DOI":"10.1111\/j.1365-2125.2003.02060.x","article-title":"Meta-analysis of large randomized controlled trials to evaluate the impact of statins on cardiovascular outcomes","volume":"57","author":"Cheung","year":"2004","journal-title":"Br J Clin Pharmacol"},{"issue":"2","key":"2026030916264695900_bib22","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1093\/qjmed\/hcq165","article-title":"Efficacy and safety of statin treatment for cardiovascular disease: a network meta-analysis of 170,255 patients from 76 randomized trials","volume":"104","author":"Mills","year":"2011","journal-title":"QJM"},{"issue":"8","key":"2026030916264695900_bib23","doi-asserted-by":"crossref","first-page":"754","DOI":"10.1001\/jama.2022.12138","article-title":"Statin use for the primary prevention of cardiovascular disease in adults: updated evidence report and systematic review for the US Preventive Services Task Force","volume":"328","author":"Chou","year":"2022","journal-title":"JAMA"},{"issue":"18","key":"2026030916264695900_bib24","doi-asserted-by":"crossref","first-page":"18889","DOI":"10.1002\/cam4.6528","article-title":"Statin use, survival and incidence of thrombosis among older patients with polycythemia vera and essential thrombocythemia","volume":"12","author":"Podoltsev","year":"2023","journal-title":"Cancer Med"},{"issue":"20","key":"2026030916264695900_bib25","doi-asserted-by":"crossref","first-page":"2021","DOI":"10.1016\/j.jacc.2022.03.354","article-title":"Reduced heart failure and mortality in patients receiving statin therapy before initial acute coronary syndrome","volume":"79","author":"Bugiardini","year":"2022","journal-title":"J Am Coll Cardiol"},{"issue":"4","key":"2026030916264695900_bib26","first-page":"H859","article-title":"Statin therapy improves locomotor muscle microvascular reactivity in patients with heart failure with preserved ejection fraction","volume":"327","author":"Iacovelli","year":"2024","journal-title":"Am J Physiol Heart Circ Physiol"},{"issue":"1","key":"2026030916264695900_bib27","doi-asserted-by":"crossref","first-page":"2953","DOI":"10.1038\/s41467-024-47327-z","article-title":"Statins improve cardiac endothelial function to prevent heart failure with preserved ejection fraction through upregulating circRNA-RBCK1","volume":"15","author":"Li","year":"2024","journal-title":"Nat Commun"},{"issue":"12","key":"2026030916264695900_bib28","doi-asserted-by":"crossref","first-page":"3359","DOI":"10.1111\/jth.15095","article-title":"Endothelial JAK2V617F mutation leads to thrombosis, vasculopathy, and cardiomyopathy in a murine model of myeloproliferative neoplasm","volume":"18","author":"Castiglione","year":"2020","journal-title":"J Thromb Haemost"},{"issue":"9","key":"2026030916264695900_bib29","doi-asserted-by":"crossref","first-page":"1960","DOI":"10.1161\/ATVBAHA.124.321008","article-title":"Decoding endothelial MPL and JAK2V617F mutation: insight into cardiovascular dysfunction in myeloproliferative neoplasms","volume":"44","author":"Zhang","year":"2024","journal-title":"Arterioscler Thromb Vasc Biol"},{"issue":"15","key":"2026030916264695900_bib30","doi-asserted-by":"crossref","first-page":"1980","DOI":"10.1182\/bloodadvances.2018018051","article-title":"Development of a prognostically relevant cachexia index in primary myelofibrosis using serum albumin and cholesterol levels","volume":"2","author":"Tefferi","year":"2018","journal-title":"Blood Adv"},{"issue":"9","key":"2026030916264695900_bib31","doi-asserted-by":"crossref","first-page":"2462","DOI":"10.3390\/biomedicines11092462","article-title":"Functionally relevant cytokine\/receptor axes in myelofibrosis","volume":"11","author":"Pozzi","year":"2023","journal-title":"Biomedicines"}],"container-title":["Blood Advances"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/10\/5\/1603\/2506243\/blooda_adv-2025-018724-main.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/10\/5\/1603\/2506243\/blooda_adv-2025-018724-main.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,9]],"date-time":"2026-03-09T20:26:55Z","timestamp":1773088015000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article\/10\/5\/1603\/565892\/Impact-of-statin-use-on-cardiovascular-and"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,27]]},"references-count":31,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2026,3,10]]}},"URL":"https:\/\/doi.org\/10.1182\/bloodadvances.2025018724","relation":{},"ISSN":["2473-9529","2473-9537"],"issn-type":[{"value":"2473-9529","type":"print"},{"value":"2473-9537","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,3,10]]},"published":{"date-parts":[[2026,2,27]]}}}